Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 16.1% | 10.4% | -14% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 74.8% | 89.8% | 89.5% | 85% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | -$0 | $0 |
| % Margin | -31.4% | 7.3% | -6.8% | 12.3% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | $0 | -$0 | $0 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | $0 |
| % Margin | -23.5% | 13.6% | -7.9% | 8.8% |
| EPS | -0.8 | 0.4 | -0.21 | 0.28 |
| % Growth | -300% | 290.5% | -175% | – |
| EPS Diluted | -0.8 | 0.4 | -0.21 | 0.27 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -19.1% | 20.2% | 11.9% | 26% |